Kalil Al-Nassir, MD
Pulmonary Disease · Amarillo, TXNPI 1639303829
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.1%), education and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by GSK at 29.6% of the total. Reporting peaked in 2024 at $7,779 and has fallen 82.1% since, to $1,395 in 2025. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 74 payments — averaging $348.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$8K
- Intuitive Surgical$8K
- Boehringer Ingelheim$7K
- Olympus Corporation Of The Americas$2K
- AstraZeneca$1K
- Insmed, Inc.$225
- plus $317 from 9 others
Across 47 payments — averaging $4633.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$110K
- GSK$79K
- Sanofi US Services Inc.$16K
- Amgen$13K
What the payments were for
- Speaking & faculty fees$14,18555%
- Travel & lodging$2,88711%
- Food & beverage$9724%
- Education$7,72130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 13 | $7,624 |
| Intuitive Surgical | 3 | $7,500 |
| Boehringer Ingelheim | 13 | $7,432 |
| Olympus Corporation Of The Americas | 10 | $1,522 |
| AstraZeneca | 14 | $1,146 |
| Insmed, Inc. | 8 | $225 |
| Regeneron Healthcare Solutions, Inc. | 4 | $142 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Philips North America LLC | 2 | $30 |
| Genentech USA, Inc. | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Grifols USA, LLC | 1 | $21 |
| Baxter Healthcare | 1 | $17 |
| Siemens Medical Solutions USA, Inc. | 1 | $16 |
| Sanofi | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$7,475
- Da Vinci Surgical System$4,500
- ION$3,000
- BREZTRI$787
How this compares
$25,766 in reported general payments places this provider in the 90th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 112 | $93,309 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $22,826 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $11,369 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $11,050 |
| Spiriva RespimatTiotropium Bromide | 14 | $7,120 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $6,658 |
| BreynaBudesonide/Formoterol Fumarate | 21 | $3,527 |
| DuleraMometasone/Formoterol | 11 | $3,375 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $1,325 |
| Montelukast Sodium | 58 | $483 |
| Prednisone | 11 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $7,624 | $127,503182 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $7,432 | $13,77828 claims |
| AstraZenecaSymbicort | $1,146 | $11,05026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Amarillo
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
- Jefy MathewThe Woodlands$318K
- Rodolfo Estrada AnzuetoSan Antonio$300K
- Zeenat SafdarHouston$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.